GenSight Biologics Announces a Successful Offering for an Am

GenSight Biologics shares resume trading today



Over €9.2 million offering of ABSA composed of a reserved offering aimed at specialized investors and a private placement



More than 50% of the...

Related Keywords

South Africa , Canada , Australia , Paris , France General , France , United States , Saint Antoine , Aquitaine , French , Bpifrance Financement , Gensight Biologics , Gensight Biologics Euronext , Laurence Rodriguez , European Parliament , Armistice Capital Master Fund Ltd , Goldman Sachs Group Inc , Euronext , Company Board Of Directors , European Union , Regulatory News , Sight Biologics , Offering Price , Heights Capital , French Commercial Code , Offering New , Reserved Offering New Shares , Reserved Offering Warrants , Offering Warrants , French Monetary , Financial Code , General Meeting , Placement New , Private Placement New Shares , Reserved Offering , Private Placement Warrants , Placement Warrants , Reserved Offering Warrants Shares , Eligible Investors , Private Placement , Prospectus Regulation , Securities Act , Sofinnova Partners , Euronext Paris , Reference Price , Warrant Share , Exercise Ratio , New Shares , Euroclear France , Warrants Shares , Exercise Period , Invest Securities , Warrant Shares , Goldman Sachs Group , Capital Master Fund , Armistice Capital Master Fund , Registration Document , French Autorit , Securities Note , Faubourg Saint Antoine , Sight Biologic , Mitochondrial Targeting Sequence , Leber Hereditary Optic Neuropathy , Gensight Biologic , Member States , European Economic Area , Target Market , Placement Agents , Markets ,